Atherosclerosis and Lipoproteins |
From the Department of Cardiology (S.W.E.v.d.P., T.J.R., J.W.J., A.v.d.L.), Leiden University Medical Center, Leiden; the Interuniversity Cardiology Institute of the Netherlands (S.W.E.v.d.P., A.v.d.L.), Utrecht; the Gaubius Laboratory (O.L.V., H.M.G.P., L.M.H.), TNO-PG, Leiden; and the Laboratory for Intensive Care Research and Optical Spectroscopy (S.W.E.v.d.P., T.C.B.S., G.J.P.), Erasmus University, Rotterdam, the Netherlands.
Correspondence to Gerwin J. Puppels, PhD, Laboratory for Intensive Care Research and Optical Spectroscopy, Erasmus University Rotterdam and University Hospital Rotterdam "Dijkzigt," Surgery 10 M, Dr Molenwaterplein 40, 3015 GD Rotterdam, The Netherlands. E-mail puppels{at}hlkd.azr.nl
Abstract Quantitative characterization of atherosclerotic plaque composition with standard histopathological methods remains limited to sectioned plaques. Raman spectroscopy enables nondestructive quantification of atherosclerotic plaque composition. We used Raman spectroscopy to study the effects of diet and lipid-lowering therapy on plaque development in apolipoprotein (APO) E*3-Leiden transgenic mice. Raman spectra were obtained over the full width and entire length of the ascending aorta and aortic arch. Spectra were modeled to calculate the relative dry weights of cholesterol and calcium salts, and quantitative maps of their distribution were created. In male mice (n=20) that received a high-fat/high-cholesterol (HFC) diet for 0, 2, 4, or 6 months, Raman spectroscopy showed good correlation between cholesterol accumulation and total serum cholesterol exposure (r
0.87, P<0.001). In female mice (n=10) that were assigned to an HFC diet, with or without 0.01% atorvastatin, a strong reduction in cholesterol accumulation (57%) and calcium salts (97%) (P<0.01) was demonstrated in the atorvastatin-treated group. In conclusion, Raman spectroscopy can be used to quantitatively study the size and distribution of depositions of cholesterol and calcification in APOE*3-Leiden transgenic mice. This study encourages Raman spectroscopy for the quantitative investigation of atherosclerosis and lipid-lowering therapy in larger animals or humans in vivo.
Key Words: atherosclerosis Raman spectroscopy cholesterol calcification lipid-lowering treatment
This article has been cited by other articles:
![]() |
S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra Mouse Models for Atherosclerosis and Pharmaceutical Modifiers Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1706 - 1721. [Abstract] [Full Text] [PDF] |
||||
![]() |
N M Rajamannan, M Subramaniam, S R Stock, N J Stone, M Springett, K I Ignatiev, J P McConnell, R J Singh, R O Bonow, and T C Spelsberg Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve Heart, June 1, 2005; 91(6): 806 - 810. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Willerson and P. M. Ridker Inflammation as a Cardiovascular Risk Factor Circulation, June 1, 2004; 109(21_suppl_1): II-2 - II-10. [Abstract] [Full Text] [PDF] |
||||
![]() |
S W E van de Poll, K Kastelijn, T C B. Schut, C Strijder, G Pasterkamp, G J Puppels, and A van der Laarse On-line detection of cholesterol and calcification by catheter based Raman spectroscopy in human atherosclerotic plaque ex vivo Heart, September 1, 2003; 89(9): 1078 - 1082. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Aktas, S. Waiczies, A. Smorodchenko, J. Dorr, B. Seeger, T. Prozorovski, S. Sallach, M. Endres, S. Brocke, R. Nitsch, et al. Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through Atorvastatin J. Exp. Med., March 17, 2003; 197(6): 725 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bea, E. Blessing, B. Bennett, M. Levitz, E. P. Wallace, and M. E. Rosenfeld Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering Arterioscler. Thromb. Vasc. Biol., November 1, 2002; 22(11): 1832 - 1837. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |